Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
autoimmune disease
Biotech
Harbour ships phase 3 data to take lead in autoimmune race
Harbour is the first company to show an anti-FcRn drug improves generalized myasthenia gravis in China, putting it ahead of rivals such as J&J.
Nick Paul Taylor
Mar 6, 2023 6:50am
Merck KGaA pays Aqilion €10M to tackle tough autoimmune target
Feb 16, 2023 6:00am
Horizon racks up 2nd win in Sjögren's to claim unique double
Jan 18, 2023 9:30am
Lilly pays $55M to ride TRex into regulatory T-cell space
Jan 9, 2023 9:10am
Vera finally snags a win for Merck KGaA kidney disease castoff
Jan 3, 2023 4:01pm
Gilead hopes to evoke new autoimmune treatments with $659M deal
Jan 3, 2023 11:11am
